<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

Recently, it was suggested that consensus molecular subtyping (CMS) may aide in predicting response to EGFR inhibitor (cetuximab) therapies. We recently identified that <i>APC</i> and <i>TP53</i> as two tumor suppressor genes, when mutated, may enhance cetuximab sensitivity a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ramya Thota, Mingli Yang, Lance Pflieger, Michael J. Schell, Malini Rajan, Thomas B. Davis, Heiman Wang, Angela Presson, Warren Jack Pledger, Timothy J. Yeatman
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
colorectal cancer
<i>APC</i>
<i>TP53</i>
mutations
CMS classification
EGFR inhibitors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/83b5ca18ff454dabb1beb852018f41e2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/83b5ca18ff454dabb1beb852018f41e2

Ejemplares similares